Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands |
Preferred Stock |
Common Stock |
Common Shares Issuable |
Paid-In Capital |
Accumulated Deficit |
Non-Controlling Interests |
Total |
Balance at Dec. 31, 2021 |
$ 3
|
$ 101
|
|
$ 656,033
|
$ (547,463)
|
$ 117,203
|
$ 225,877
|
Balance (in shares) at Dec. 31, 2021 |
3,427,138
|
101,435,505
|
|
|
|
|
|
Balance at Mar. 31, 2022 |
$ 3
|
$ 106
|
|
660,973
|
(563,223)
|
95,719
|
193,578
|
Balance (in shares) at Mar. 31, 2022 |
3,427,138
|
106,321,875
|
|
|
|
|
|
Balance at Dec. 31, 2021 |
$ 3
|
$ 101
|
|
656,033
|
(547,463)
|
117,203
|
225,877
|
Balance (in shares) at Dec. 31, 2021 |
3,427,138
|
101,435,505
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
10,644
|
|
|
10,644
|
Issuance of common stock related to equity plans |
|
$ 3
|
|
(3)
|
|
|
|
Issuance of common stock related to equity plans (in shares) |
|
2,646,375
|
|
|
|
|
|
Issuance of common stock under ESPP |
|
|
|
99
|
|
|
99
|
Issuance of common stock under ESPP (in shares) |
|
135,464
|
|
|
|
|
|
Issuance of common stock for at-the-market offering, net |
|
$ 4
|
|
5,523
|
|
|
5,527
|
Issuance of common stock for at-the-market offering, net (in shares) |
|
3,500,303
|
|
|
|
|
|
Preferred A dividends declared and paid |
|
|
|
(4,016)
|
|
|
(4,016)
|
Partner company's at-the-market offering, net |
|
|
|
14,476
|
|
|
14,476
|
Partner company's exercise of options for cash |
|
|
|
111
|
|
|
111
|
Issuance of common stock under partner company's ESPP |
|
|
|
116
|
|
|
116
|
Partner company's dividends declared and paid |
|
|
|
(375)
|
|
|
(375)
|
Partner company's net settlement of shares withheld for taxes |
|
|
|
(1,698)
|
|
|
(1,698)
|
Reversal of partner company's common shares for research and development expenses |
|
|
|
(35)
|
|
|
(35)
|
Warrants in conjunction with Oaktree Note |
|
|
|
384
|
|
|
384
|
Non-controlling interest in partner companies |
|
|
|
(19,568)
|
|
19,568
|
|
Net loss attributable to non-controlling interest |
|
|
|
|
|
(66,292)
|
(66,292)
|
Net loss attributable to common stockholders |
|
|
|
|
(37,116)
|
|
(37,116)
|
Balance at Jun. 30, 2022 |
$ 3
|
$ 108
|
|
$ 661,691
|
(584,579)
|
70,479
|
147,702
|
Balance (in shares) at Jun. 30, 2022 |
3,427,138
|
107,717,647
|
|
661,691,000
|
|
|
|
Balance at Mar. 31, 2022 |
$ 3
|
$ 106
|
|
$ 660,973
|
(563,223)
|
95,719
|
193,578
|
Balance (in shares) at Mar. 31, 2022 |
3,427,138
|
106,321,875
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
5,081
|
|
|
5,081
|
Issuance of common stock related to equity plans (in shares) |
|
176,406
|
|
|
|
|
|
Issuance of common stock under ESPP |
|
|
|
$ 99
|
|
|
99
|
Issuance of common stock under ESPP (in shares) |
|
135,464
|
|
|
|
|
|
Issuance of common stock for at-the-market offering, net |
|
$ 2
|
|
|
|
|
1,301
|
Issuance of common stock for at-the-market offering, net (in shares) |
|
1,083,902
|
|
1,299,000
|
|
|
|
Preferred A dividends declared and paid |
|
|
|
$ (2,008)
|
|
|
(2,008)
|
Partner company's at-the-market offering, net |
|
|
|
(3,693)
|
|
|
(3,693)
|
Partner company's exercise of options for cash |
|
|
|
111
|
|
|
111
|
Partner company's dividends declared and paid |
|
|
|
(188)
|
|
|
(188)
|
Reversal of partner company's common shares for research and development expenses |
|
|
|
(35)
|
|
|
(35)
|
Non-controlling interest in partner companies |
|
|
|
(7,334)
|
|
7,334
|
|
Net loss attributable to non-controlling interest |
|
|
|
|
|
(32,574)
|
(32,574)
|
Net loss attributable to common stockholders |
|
|
|
|
(21,356)
|
|
(21,356)
|
Balance at Jun. 30, 2022 |
$ 3
|
$ 108
|
|
$ 661,691
|
(584,579)
|
70,479
|
147,702
|
Balance (in shares) at Jun. 30, 2022 |
3,427,138
|
107,717,647
|
|
661,691,000
|
|
|
|
Balance at Dec. 31, 2022 |
$ 3
|
$ 110
|
|
$ 675,841
|
(634,233)
|
8,304
|
50,025
|
Balance (in shares) at Dec. 31, 2022 |
3,427,138
|
110,494,245
|
|
|
|
|
|
Balance at Mar. 31, 2023 |
$ 3
|
$ 130
|
|
693,433
|
(655,770)
|
(17,990)
|
19,806
|
Balance (in shares) at Mar. 31, 2023 |
3,427,138
|
130,417,161
|
|
|
|
|
|
Balance at Dec. 31, 2022 |
$ 3
|
$ 110
|
|
675,841
|
(634,233)
|
8,304
|
50,025
|
Balance (in shares) at Dec. 31, 2022 |
3,427,138
|
110,494,245
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
8,948
|
|
|
8,948
|
Issuance of common stock related to equity plans |
|
$ 3
|
|
(3)
|
|
|
|
Issuance of common stock related to equity plans (in shares) |
|
2,757,850
|
|
|
|
|
|
Issuance of common stock for public offering, net |
|
$ 17
|
|
13,137
|
|
|
13,154
|
Issuance of common stock for public offering, net (in shares) |
|
16,642,894
|
|
|
|
|
|
Issuance of common stock for at-the-market offering, net |
|
$ 2
|
|
1,166
|
|
|
1,168
|
Issuance of common stock for at-the-market offering, net (in shares) |
|
1,596,381
|
|
|
|
|
|
Common shares issued for dividend on partner company's convertible preferred shares |
|
|
$ 23
|
108
|
|
|
131
|
Common shares issued for dividend on partner company's convertible preferred shares (in shares) |
|
165,999
|
|
|
|
|
|
Preferred A dividends declared and paid |
|
|
|
(4,016)
|
|
|
(4,016)
|
Partner company's offering, net |
|
|
|
21,977
|
|
|
21,977
|
Partner company's exercise of options for cash |
|
|
|
3
|
|
|
3
|
Issuance of common stock under partner company's ESPP |
|
|
|
88
|
|
|
88
|
Partner company's dividends declared and paid |
|
|
|
(371)
|
|
|
(371)
|
Reversal of partner company's common shares for research and development expenses |
|
|
|
1,233
|
|
|
1,233
|
Warrants in conjunction with Oaktree Note |
|
|
|
272
|
|
|
272
|
Deconsolidation of Aevitas noncontrolling interest |
|
|
|
|
|
5,891
|
5,891
|
Non-controlling interest in partner companies |
|
|
|
(19,486)
|
|
19,486
|
|
Net loss attributable to non-controlling interest |
|
|
|
|
|
(68,133)
|
(68,133)
|
Net loss attributable to common stockholders |
|
|
|
|
(46,313)
|
|
(46,313)
|
Balance at Jun. 30, 2023 |
$ 3
|
$ 132
|
23
|
698,897
|
(680,546)
|
(34,452)
|
(15,943)
|
Balance (in shares) at Jun. 30, 2023 |
3,427,138
|
131,657,369
|
|
|
|
|
|
Balance at Mar. 31, 2023 |
$ 3
|
$ 130
|
|
693,433
|
(655,770)
|
(17,990)
|
19,806
|
Balance (in shares) at Mar. 31, 2023 |
3,427,138
|
130,417,161
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
4,217
|
|
|
4,217
|
Issuance of common stock related to equity plans (in shares) |
|
82,728
|
|
|
|
|
|
Issuance of common stock for public offering, net |
|
|
|
(41)
|
|
|
(41)
|
Issuance of common stock for at-the-market offering, net |
|
$ 2
|
|
719
|
|
|
721
|
Issuance of common stock for at-the-market offering, net (in shares) |
|
991,481
|
|
|
|
|
|
Common shares issued for dividend on partner company's convertible preferred shares |
|
|
23
|
108
|
|
|
131
|
Common shares issued for dividend on partner company's convertible preferred shares (in shares) |
|
165,999
|
|
|
|
|
|
Preferred A dividends declared and paid |
|
|
|
(2,008)
|
|
|
(2,008)
|
Partner company's offering, net |
|
|
|
14,460
|
|
|
14,460
|
Partner company's exercise of options for cash |
|
|
|
3
|
|
|
3
|
Issuance of common stock under partner company's ESPP |
|
|
|
88
|
|
|
88
|
Partner company's dividends declared and paid |
|
|
|
(185)
|
|
|
(185)
|
Reversal of partner company's common shares for research and development expenses |
|
|
|
3
|
|
|
3
|
Warrants in conjunction with Oaktree Note |
|
|
|
272
|
|
|
272
|
Deconsolidation of Aevitas noncontrolling interest |
|
|
|
|
|
5,891
|
5,891
|
Non-controlling interest in partner companies |
|
|
|
(12,172)
|
|
12,172
|
|
Net loss attributable to non-controlling interest |
|
|
|
|
|
(34,525)
|
(34,525)
|
Net loss attributable to common stockholders |
|
|
|
|
(24,776)
|
|
(24,776)
|
Balance at Jun. 30, 2023 |
$ 3
|
$ 132
|
$ 23
|
$ 698,897
|
$ (680,546)
|
$ (34,452)
|
$ (15,943)
|
Balance (in shares) at Jun. 30, 2023 |
3,427,138
|
131,657,369
|
|
|
|
|
|